New drug aims to clear painful hand and foot pustules

NCT ID NCT03633396

Completed Disease control Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a monthly injection called imsidolimab (ANB019) in 59 adults with palmoplantar pustulosis, a chronic skin condition causing painful, pus-filled blisters on the palms and soles. The study compared the drug to a placebo to see if it could reduce the severity of the pustules and scaling. Researchers also monitored safety and side effects over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imsidolimab (ANB019)
What this could lead to: If it works, this could point toward a new treatment option for palmoplantar pustulosis, a chronic skin condition causing painful pustules on hands and feet.
What could go wrong: This is a small, early-phase trial with only 59 participants. Results may not apply to everyone, and the drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmoplantar pustulosis psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PALMOPLANTAR PUSTULOSIS

Contacts and locations

Locations

Investigational Site

Birmingham, Alabama, 35233, United States
Investigational Site

Phoenix, Arizona, 85032, United States
Investigational Site

Encino, California, 91436, United States
Investigational Site

Santa Monica, California, 90405, United States
Investigational Site

Fort Lauderdale, Florida, 33316, United States
Investigational Site

Miami, Florida, 33155, United States
Investigational Site

Pembroke Pines, Florida, 33028, United States
Investigational Site

Tampa, Florida, 33607, United States
Investigational Site

Indianapolis, Indiana, 46250, United States
Investigational Site

Plainfield, Indiana, 46168, United States
Investigational Site

Overland Park, Kansas, 66215, United States
Investigational Site

Ann Arbor, Michigan, 48109, United States
Investigational Site

St Louis, Missouri, 63110, United States
Investigational Site

St Louis, Missouri, 63117, United States
Investigational Site

Wilmington, North Carolina, 28405, United States
Investigational Site

Columbus, Ohio, 43230, United States
Investigational Site

Norman, Oklahoma, 73071, United States
Investigational Site

Portland, Oregon, 97239, United States
Investigational Site

Dallas, Texas, 75230, United States
Investigational Site

Surrey, British Columbia, Canada
Investigational Site

Greater Sudbury, Ontario, Canada
Investigational Site

Markham, Ontario, Canada
Investigational Site

Drummondville, Quebec, Canada
Investigational Site

Montreal, Quebec, Canada
Investigational Site

Bad Bentheim, 48455, Germany
Investigational Site

Berlin, 10117, Germany
Investigational Site

Berlin, 10789, Germany
Investigational Site

Bonn, 53127, Germany
Investigational Site

Hamburg, 20253, Germany
Investigational Site

Hamburg, 22391, Germany
Investigational Site

Schwerin, 19055, Germany
Investigational Site

Gdansk, 80-546, Poland
Investigational Site

Katowice, 40-611, Poland
Investigational Site

Lodz, 90-265, Poland
Investigational Site

Olsztyn, 10-229, Poland
Investigational Site

Ostrowiec Świętokrzyski, 27-400, Poland
Investigational Site

Rzeszów, 35-055, Poland
Investigational Site

Szczecin, 70-332, Poland
Investigational Site

Wroclaw, 50-566, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.